ArticleMolecular biotechnology2022
Protective Effects of Catalpol on Limb Motor Function and Ultrastructure of Hippocampal Neurons in Rats with Cerebral Ischemia.
Article in Molecular biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Catalpol: an natural multifunctional iridoid glycoside with promising therapeutic properties.Frontiers in molecular biosciences · 2026Review
- A study on the mechanism of Beclin-1 m6A modification mediated by catalpol in protection against neuronal injury and autophagy following cerebral ischemia.Molecular medicine (Cambridge, Mass.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to examine the protective effects of catalpa on ultrastructure of hippocampal neuron and limb motor function in rats with cerebral ischemia. 90 healthy Sprague-Dawley male rats were randomly divided into control (n = 30) and model (n = 60) groups. Cerebral ischemia and hippocampal neurons were induced by occluding the internal carotid artery and injection of high blood glucose, respectively. Model rats were randomly divided into routine (n = 30) and observational (n = 30) groups. Animals in the routine group received edaravone injection (7 mg/kg/day) for 14 days, while rats in the observation group were treated with catalpol (30 mg/kg/day) for 14 days. Limb motor function score, fine motion execution capability, number of hippocampal neurons retained, and the ultrastructure of hippocampal nerve cells were considered at 3, 7, and 14 days after treatments. A significant difference was observed in the mean scores of limb motor function, fine motor execution ability, and the number of hippocampal neurons retained between groups (p < 0.001). Repetitive treatments with catalpol significantly improved the mean number of hippocampal neurons retained (p < 0.01), limb motor function (p < 0.001), and fine motor execution ability scores (p < 0.01) at 3, 7, and 14 days compared to edaravone. Catalpol treatments also improved the ultrastructure morphology of neuronal cells. Catalpa can effectively improve limb motor function and protect hippocampal neuron function in rats with cerebral ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.